Improving Submission Quality: Preparing For Regulatory Differences

By Xiaoxia Li

Pharmaceutical and biopharmaceutical executives who decide to file their clinical trial applications with multiple regulatory agencies often find the global submission path attractive because of the time-saving and budget efficiencies within testing and reporting. But, if companies are not accounting for the distinct regulatory requirement differences, they could put their submission, and ultimately their product development, in jeopardy.